Abstract
Regulatory T lymphocytes (Treg) modulate the destruction of abnormal cells through the binding of tumor necrosis factor (TNF) to tumor necrosis factor receptor 2 (TNFR2) on its surface. The TNFR2 is encoded by the TNFRSF1B polymorphic gene, and therefore, healthy individuals may be at distinct risks of CM and CM patients may have tumors of different behaviors. This study aimed to evaluate the roles of TNFRSF1B c.587T>G, c.*188A>G, c.*215C>T, and c.*922C>T single nucleotide variants (SNVs) in risk, clinicopathological aspects, and survival of CM patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
